Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Lupus
|
May 5, 2025
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sébastien J Hotte, Hal W Hirte, Eric X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
Lupus Science & Medicine
|
December 28, 2018
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
Ronald F van Vollenhoven, William Stohl, Richard A Furie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
BMJ Supportive & Palliative Care
|
October 12, 2021
Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study
Nicola Cassidy, Lynn Fox, Maria Love, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
Constantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
ERJ Open Research
|
July 28, 2020
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?
Christopher J Brereton, Timothy Wallis, Michelle Casey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
Stephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
Rheumatology (Oxford, England)
|
May 22, 2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Eline J Arends, Mihaela Zlei, Christopher M Tipton, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Lupus
|
May 5, 2025
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sébastien J Hotte, Hal W Hirte, Eric X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
Lupus Science & Medicine
|
December 28, 2018
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
Ronald F van Vollenhoven, William Stohl, Richard A Furie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
BMJ Supportive & Palliative Care
|
October 12, 2021
Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study
Nicola Cassidy, Lynn Fox, Maria Love, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
Constantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
ERJ Open Research
|
July 28, 2020
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?
Christopher J Brereton, Timothy Wallis, Michelle Casey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
Stephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
Rheumatology (Oxford, England)
|
May 22, 2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Eline J Arends, Mihaela Zlei, Christopher M Tipton, et al.
Page
of 4